As survival gains have been witnessed in the addition of bevacizumab to immunochemotherapy among first-line populations, including those difficult-to-treated patients harboring liver metastases, this combination strategy is approved for the treatment of metastatic nonsquamous NSCLC without EGFR/ALK genetic alterations [1, 30, 31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.